کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
5903508 | 1157083 | 2012 | 9 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Leptin replacement therapy does not improve the abnormal lipid kinetics of hypoleptinemic patients with HIV-associated lipodystrophy syndrome
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
HDL-CLDL-CFFAGSTAUC - AUCGlucagon stimulation test - آزمون تحریک گلوکاگونFree fatty acid - اسید چرب آزادFat oxidation - اکسیداسیون چربیgeneralized estimating equations - برآورد معادلات تعمیم یافتهTriglycerides - تریگلیسریدGEE - جیbody mass index - شاخص توده بدنBMI - شاخص توده بدنیnon-HDL-C - غیر HDL-CLipolysis - لیپولیزLeptin resistance - مقاومت لپتینarea under the curve - منطقه تحت منحنیrate of appearance - نرخ ظاهرhigh density lipoprotein cholesterol - کلسترول لیپوپروتئین با چگالی بالاlow density lipoprotein cholesterol - کلسترول لیپوپروتئین با چگالی کم
موضوعات مرتبط
علوم زیستی و بیوفناوری
بیوشیمی، ژنتیک و زیست شناسی مولکولی
علوم غدد
پیش نمایش صفحه اول مقاله
چکیده انگلیسی
Patients with HIV-associated dyslipidemic lipodystrophy (HADL) have characteristic lipid kinetic defects: accelerated lipolysis, blunted fat oxidation and increased hepatic fatty acid reesterification. HADL patients with lipoatrophy also have leptin deficiency. Small or non-randomized studies have suggested that leptin replacement improves glucose metabolism in HADL, with very limited data regarding its effects on the lipid kinetic abnormalities. We performed a randomized, double-blind, placebo-controlled, dose-escalating (0.02Â mg/kg/d for two months; 0.04Â mg/kg/d for a further two months) study of the effects of metreleptin on lipid kinetics in 17 adults with HADL, hypertriglyceridemia and hypoleptinemia. Rates of lipolysis, intra-adipocyte and intrahepatic reesterification and fatty acid oxidation were measured using infusions of 13C1-palmitate and 2H5-glycerol, and indirect calorimetry. Fasting lipid profiles and glucose and insulin responses to oral glucose challenge were also measured. Metreleptin treatment induced significant, dose-dependent increases in fasting plasma leptin levels. There was no significant change in total lipolysis, net lipolysis, adipocyte or hepatic re-esterification or fatty acid oxidation, or in fasting triglyceride or HDL-C concentrations, with metreleptin treatment. Metreleptin decreased fasting non-HDL-C levels (PÂ <Â .01) and area-under-the-curve for glucose (PÂ <Â .05). In hypoleptinemic HADL patients, treatment with metreleptin at 0.02 or 0.04Â mg/kg/d does not improve abnormal fasting lipid kinetics, or triglyceride or HDL-C levels. Metreleptin does, however, improve glycemia and non-HDL-C in these patients. These results suggest a dissociation between leptin's effects on glucose metabolism compared to those on lipid kinetics in HADL.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Metabolism - Volume 61, Issue 10, October 2012, Pages 1395-1403
Journal: Metabolism - Volume 61, Issue 10, October 2012, Pages 1395-1403
نویسندگان
Rajagopal V. Sekhar, Farook Jahoor, Dinakar Iyer, Anuradha Guthikonda, Jaya Paranilam, Fareed Elhaj, Ivonne Coraza, Ashok Balasubramanyam,